Key Stats
Founded: 1887 in Allegan, Michigan
Headquarters: Dublin, Ireland (legal) and Grand Rapids, Michigan (operational)
CEO: Patrick Lockwood-Taylor (since June 2023)
Employees: Approximately 8,400
NYSE Ticker Symbol: PRGO
Perrigo Company plc operates as the world’s largest manufacturer of store brand over-the-counter pharmaceutical products. The company develops, manufactures, and distributes consumer self-care products across the United States, Europe, and international markets.
Perrigo operates through two primary segments: Consumer Self-Care Americas and Consumer Self-Care International. The product portfolio includes pain relief, cough and cold remedies, digestive health, skin care, women’s health products, vitamins, and infant formula.
The company generated $4.37 billion in revenue in 2024. Perrigo serves major retail chains, supermarkets, and e-commerce platforms by providing affordable healthcare alternatives to name-brand products through private-label manufacturing.
Perrigo Co. History
The Perrigo story began in 1887 when Luther Perrigo launched a business packaging and distributing patented medicines from a general store in Allegan, Michigan. By the early 1920s, as many as 50 salesmen called on rural stores throughout the Midwest selling Perrigo products.
The company pioneered the private label concept by offering to imprint individual store names on products at no extra cost. This strategy built customer loyalty and established Perrigo’s core business model that continues today.
1887
Luther Perrigo founded the L. Perrigo Company in Allegan, Michigan, packaging medicines and household items for general stores.
1921
First manufacturing plant opened in Allegan. A second plant followed in 1936 as production expanded.
1991
Perrigo completed its initial public offering on Nasdaq, raising capital for expansion into new product categories.
1997
Entered the Mexican market through acquisition of Quimica y Farmacia (Quifa), beginning international expansion.
2005
Acquired Agis Industries in Israel for $850 million, adding generic pharmaceutical and active ingredient capabilities.
2010
Purchased PBM Holdings to become a leading manufacturer of store brand infant formula in North America.
2013
Acquired Elan Corporation for $8.6 billion, reincorporating as an Irish company (Perrigo Company plc).
2015
Completed $4.5 billion acquisition of Omega Pharma, becoming a major branded OTC player in Europe.
2022
Acquired HRA Pharma for $2.1 billion. Moved headquarters from Allegan to Grand Rapids, Michigan.
2023
FDA approved Opill, the first over-the-counter daily birth control pill in the U.S., manufactured by Perrigo subsidiary HRA Pharma.
Perrigo Co. Co-founders
Luther Perrigo
Founded the company in 1887 as the proprietor of a general store and apple-drying business in Allegan, Michigan. Pioneered the private-label concept in consumer healthcare.
Charles Perrigo
Co-founded L. Perrigo Company alongside Luther Perrigo. The brothers ran a general store together before expanding into pharmaceutical distribution.
Perrigo Co. Competitors
Perrigo competes against multinational pharmaceutical and consumer healthcare companies in the private-label and branded OTC markets. Key competitors include major players in generic drugs, store brand products, and consumer self-care segments across North America and Europe.
| Company | Headquarters | Key Products |
|---|---|---|
| Haleon | Weybridge, United Kingdom | OTC medicines, oral care, vitamins |
| Kenvue | Skillman, New Jersey | Tylenol, Band-Aid, Listerine |
| Procter & Gamble | Cincinnati, Ohio | Vicks, Pepto-Bismol, personal care |
| Reckitt Benckiser | Slough, United Kingdom | Mucinex, Nurofen, Gaviscon |
| Bayer | Leverkusen, Germany | Aspirin, Aleve, One-A-Day vitamins |
| Teva Pharmaceuticals | Tel Aviv, Israel | Generic drugs, OTC medicines |
| Viatris | Canonsburg, Pennsylvania | Generic drugs, biosimilars |
| Dr. Reddy’s Laboratories | Hyderabad, India | Generic pharmaceuticals, APIs |
| Sandoz | Basel, Switzerland | Generic drugs, biosimilars |
| Abbott | Abbott Park, Illinois | Infant formula, nutritional products |
Perrigo Co. Revenue
Perrigo Co. generated $4.37 billion in net sales during fiscal year 2024. The Consumer Self-Care Americas segment contributed approximately $3 billion while Consumer Self-Care International provided the remainder of revenue.
Perrigo Co. Annual Revenue (in Billions USD)
Perrigo Co. Acquisitions
Perrigo has grown through strategic acquisitions across multiple continents, transforming from a regional private-label manufacturer to a global consumer self-care company. The company has completed over 20 acquisitions spanning pharmaceutical manufacturing, branded OTC products, and infant nutrition.
The 2005 acquisition of Agis Industries for $850 million marked a significant expansion into Israel. This purchase added generic pharmaceutical capabilities and active pharmaceutical ingredient (API) production. In 2010, the PBM Holdings acquisition established Perrigo as a leading store brand infant formula manufacturer serving retailers across North America.
The transformative 2013 acquisition of Elan Corporation for $8.6 billion enabled Perrigo to reincorporate as an Irish company. This corporate restructuring reduced the company’s effective tax rate through what became known as a tax inversion. The transaction represented one of the largest such inversions in U.S. corporate history.
Omega Pharma’s $4.5 billion acquisition in 2015 made Perrigo a major branded OTC player in Europe. The purchase added well-known brands across multiple healthcare categories. In 2019, the $750 million Ranir Global Holdings acquisition strengthened oral care offerings through the Plackers brand.
More recently, Perrigo acquired HRA Pharma for $2.1 billion in 2022. This deal brought ellaOne emergency contraception and led to FDA approval of Opill, the first OTC daily birth control pill. The company also divested its generics business to Altaris Capital Partners for $1.55 billion in 2021 to focus on consumer self-care products.
Perrigo Co. Marketcap
Perrigo Co. has a market capitalization of approximately $1.77 billion as of late 2025. The company peaked at over $18 billion in market value during 2015 when Mylan made a $29 billion acquisition offer that shareholders rejected.
Perrigo Co. Market Capitalization (in Billions USD)
FAQs
When was Perrigo Co. founded?
Perrigo was founded in 1887 by Luther and Charles Perrigo in Allegan, Michigan. The company started as a general store operation that packaged and distributed medicines before evolving into a pharmaceutical manufacturer.
Who is the CEO of Perrigo Co.?
Patrick Lockwood-Taylor serves as President and CEO of Perrigo Company plc. He joined the company in June 2023 after previously holding leadership positions at Bayer and Procter & Gamble.
Where is Perrigo Co. headquartered?
Perrigo is legally headquartered in Dublin, Ireland, for tax purposes. The company’s North American operational headquarters is located in Grand Rapids, Michigan, within Michigan State University’s Innovation Park.
What products does Perrigo Co. make?
Perrigo manufactures store brand OTC medications, infant formula, vitamins, pain relievers, cough and cold remedies, digestive health products, and skin care items. Branded products include Opill, Mederma, Compeed, and Solpadeine.
What is Perrigo Co. market capitalization?
Perrigo has a market capitalization of approximately $1.77 billion as of late 2025. The company trades on the New York Stock Exchange under the ticker symbol PRGO.
